Table 1.
Clinical characteristics of HP subjects and controls
| HP (%) | Control (%) | P value | |
|---|---|---|---|
| Subjects | 226 | 1355 | |
| Sex (male/female) | 92 (41)/134 (59) | 570 (42)/785 (58) | 0.7 |
| Age | 61.2±10.4 | 59.2±10.0 | 0.0005 |
| Smoking history (ever/never) | 117 (54)/100 (46) | 1170 (86)/175 (14) | <0.0001 |
| Pulmonary function | |||
| %FVC (N=167) | 65.5±21.5 | NA | |
| %DLco (N=150) | 52.2±20.5 | NA | |
| GAP index (N=148) | |||
| Stage1 | 89 (60) | NA | |
| Stage2 | 49 (33) | NA | |
| Stage3 | 10 (7) | NA | |
| Fibrosis (yes/no/unknown) | 152 (67) /47 (21)/27 (12) | NA | |
| CT-proven fibrosis (yes/no/unknown) | 120 (53)/8 (4)/98 (43) | NA | |
| Pathology proven fibrosis (yes/no/unknown) | 77 (34)/47 (21)/102 (45) | NA | |
| Antigen identification (yes/no/unknown) | 124 (55)/51 (23)/51 (23) | NA | |
%DLco, diffusing capacity of the lung for carbon monoxide, % of predicted value; %FVC, forced vital capacity, % of predicted value; HP, hypersensitivity pneumonitis; NA, not available.